CLEARLY COMPLIANCE LIMITED

Financial Health Score: D

Explanation: The business is exhibiting chronic symptoms of financial emaciation. While currently solvent, the patient has suffered a severe loss of financial reserves over the last four years, dropping from a robust net asset position of £89,898 in 2021 to a fragile £13,538 in 2025. The sharp deterioration in working capital and the shrinking asset base indicate a business that is surviving day-to-day but lacks the strength to withstand unexpected economic shocks.

1. Key Vital Signs

• Net Assets (The "Blood Pressure"): £13,538 (Down 43% from 2024)
  • Interpretation: The company's financial blood pressure is dropping dangerously low. Net assets have plummeted from a healthy £89,898 in 2021 to just £13,538. Assuming the minimal £2 share capital has remained constant, this £76,360 drop represents a significant hemorrhage of retained profits, indicating sustained operational losses or heavy dividend extractions that have drained the company's reserves.
• Current Ratio (The "Pulse Rate"): 1.19 (Down from 1.95 in 2024)
  • Interpretation: Calculated as Current Assets (£40,425) divided by Current Liabilities (£33,740). A ratio of 1.19 means the business has just £1.19 in short-term assets for every £1 of short-term debt owed. This is barely above the critical 1.0 threshold. The patient's pulse is weakening; there is very little margin of safety to cover immediate obligations if a creditor calls in a debt or a customer delays payment.
• Working Capital / Net Current Assets (The "Immune System"): £6,685 (Down 75% from £26,906 in 2024)
  • Interpretation: Working capital acts as the immune system against day-to-day operational hiccups. With less than £7,000 in the tank to fund a business employing 8 people, the company has virtually no buffer against unexpected costs. This severe drop leaves the business highly vulnerable to cash flow viruses.
• Total Assets (The "Muscle Mass"): £42,686 (Down 25% from 2024, and down 78% from the 2021 peak of £195,786)
  • Interpretation: The business has experienced severe muscular atrophy. The dramatic drop in total assets from 2021 to 2025 suggests the company has either written off bad debts, depleted its cash reserves, or distributed assets out of the business.

2. Diagnosis

Chronic Financial Emaciation with Acute Working Capital Strain

The financial data reveals a business that has been steadily deteriorating since a notable peak in 2021. While the company is technically solvent (assets exceed liabilities), it is suffering from "working capital anemia."

The most alarming symptom is the rapid contraction of the balance sheet. The business has shed over £76,000 in net value over four years. Furthermore, there is a dangerous shift in the liability structure: short-term creditors have increased to £33,740, while long-term creditors have shifted from a liability of £5,086 to what appears to be an asset or negative liability of £4,592. This suggests the business may have restructured debts, pushing long-term obligations into short-term ones, which places immense immediate pressure on cash flow.

With 8 employees and a micro-entity balance sheet of this size, the business appears to be running incredibly lean—perhaps too lean. The current financial structure lacks the resilience required for a company operating in the financial intermediation sector, where trust and liquidity are paramount.

3. Recommendations

To stabilize the patient and restore financial wellness, the following immediate interventions are required:

1. Stop the Bleeding (Cash Flow Management): With working capital at a perilous £6,685, immediate action is needed to protect cash. Freeze any non-essential expenditure and rigorously chase outstanding debtor payments to inject liquidity into the business.
2. Reduce the Cholesterol (Short-term Creditors): The £33,740 in current liabilities is clogging the company's financial arteries. Negotiate extended payment terms with suppliers to stretch out the payables and relieve the immediate cash flow burden.
3. Rehydrate the Reserves (Capital Injection): The £13,538 net asset position is dangerously thin for a company of this age and sector. The directors/shareholders should consider injecting fresh capital to bolster the balance sheet and restore a healthy working capital buffer.
4. Investigate the Atrophy: Conduct a strict review of the 2021-2025 period to understand exactly why net assets declined by £76,360. If the drop was due to trading losses, the underlying business model needs urgent review. If it was due to large dividend payouts, the directors must acknowledge that they have stripped the business of its operational safety net.